Therapies

As of 2024, there are no approved therapies that can halt or reverse the neurodegenerative processes in PD. Research efforts are focused on developing neuroprotective agents aimed at slowing disease progression. Potential strategies under investigation include targeting alpha-synuclein aggregation, enhancing mitochondrial function, and modulating neuroinflammation. However, these approaches remain experimental, and their efficacy has yet to be conclusively demonstrated in clinical settings.

• Levodopa: The most effective treatment, levodopa is a precursor to dopamine that crosses the blood-brain barrier. It is often combined with carbidopa to inhibit peripheral metabolism, thereby increasing central nervous system availability.
• Dopamine Agonists: These agents directly stimulate dopamine receptors and can be used as monotherapy in early PD or as adjuncts to levodopa in advanced stages. They may have a lower risk of motor complications but are associated with side effects such as impulse control disorders. 
• Monoamine Oxidase-B (MAO-B) Inhibitors: Drugs like selegiline and rasagiline inhibit the breakdown of dopamine, thereby prolonging its action. They are typically used in early PD or as adjuncts to levodopa. 

Non-dopaminergic therapies target other neurotransmitter systems to manage PD symptoms:

• Anticholinergics: These agents can help reduce tremors but are limited by side effects such as cognitive impairment, particularly in older adults.
• Amantadine: Originally an antiviral, amantadine has modest efficacy in reducing dyskinesias and may provide symptomatic relief. 

Emerging evidence suggests that neuroinflammation and metabolic dysfunction play roles in PD pathogenesis. Research into anti-inflammatory agents and metabolic modulators is ongoing, but these approaches have not yet translated into approved treatments.

Devices

View More

Surgical interventions, particularly deep brain stimulation (DBS), are considered for patients with advanced PD who have inadequate symptom control with medication. DBS involves implanting electrodes into specific brain regions to modulate neural activity. Recent advancements include adaptive DBS systems that adjust stimulation in real-time based on neural feedback, potentially improving efficacy and reducing side effects.

Additionally, the FDA has approved continuous subcutaneous infusions of levodopa-based therapies, such as AbbVie’s vyalev, to provide steady dopamine levels and manage motor fluctuations in advanced PD. 

Diet and Nutrition

View More

Dietary management in PD focuses on optimizing gastrointestinal function and medication efficacy:

• Fiber and Hydration: Increased intake of dietary fiber and fluids can alleviate constipation, a common non-motor symptom. 
• Protein Distribution: Since dietary proteins can interfere with levodopa absorption, some patients benefit from consuming protein-rich meals in the evening to enhance medication effectiveness during the day. 
• Antioxidant-Rich Foods: Emerging research suggests that foods high in antioxidants, such as certain types of seaweed, may have neuroprotective properties, although more studies are needed to confirm these benefits. 

Supplements

View More

Various dietary supplements, including coenzyme Q10, creatine, and vitamins E and C, have been investigated for potential neuroprotective effects in PD. However, clinical trials have not consistently demonstrated their efficacy in altering disease progression. Patients should consult healthcare providers before initiating any supplement regimen. 

Clinical Trials

View More

Ongoing clinical trials are exploring a range of therapeutic strategies for PD:

• Gene Therapy: Approaches aim to deliver genes that enhance dopamine synthesis or provide neuroprotection directly to affected brain regions. While early-phase trials have shown promise, further research is needed to establish long-term safety and efficacy.
• Cell-Based Therapies: Transplantation of stem cell-derived dopaminergic neurons is under investigation as a means to replace lost neurons. Clinical trials are ongoing to assess the viability and functional integration of these cells in patients.
• Novel Pharmacological Agents: Compounds targeting non-dopaminergic pathways, such as serotonergic and glutamatergic systems, are being tested to address symptoms unresponsive to traditional therapies. For example, befiradol, a selective serotonin receptor agonist, is undergoing trials for its potential to reduce levodopa-induced dyskinesia.